Pre-earnings brief
Reports
Wed, Mar 23, 2022
Est. EPS
—
Est. revenue
—
Implied move
±4.0%
EPS beat rate
63%
Soleno Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases. As part of the health care sector, its work is crucial in addressing unmet medical needs and improving patient outcomes.
Last quarter
In Q1-2026, Soleno reported an EPS of $0.59, falling short of the expected $0.73. The stock saw a slight increase of 0.02% the following day.
EPS beat streak
0Q
EPS beat rate
63%
Avg EPS surprise
+1923.32%
Avg 1-day reaction
-0.32%
Investors are cautiously optimistic about Soleno's upcoming earnings report, especially after mixed results in previous quarters. The focus will be on whether the company can meet or exceed expectations.
Bull case
If Soleno can demonstrate strong revenue growth and improve its EPS, it could signal a turnaround and boost investor confidence.
Bear case
Conversely, if the company fails to meet expectations again, it may raise concerns about its financial stability and future growth prospects.
The print will turn on these.
Q1
Will Soleno's EPS meet or exceed the expected figure?
A positive EPS could indicate improved profitability and reassure investors after recent misses.
Q2
What are the revenue figures for this quarter?
Strong revenue growth is essential for the company's future and will be closely scrutinized by investors.
Why consensus could be wrong
The market may underestimate Soleno's potential for revenue growth, given its recent product developments and market positioning.
Supporting evidence
The company has a history of surprising analysts with better-than-expected results, as seen in previous quarters.
Options pricing suggests a higher volatility expectation than historical movements, indicating potential for a significant shift.
Key risk
If the revenue growth exceeds expectations, it could significantly alter the market's perception of Soleno's future.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it follows a series of mixed results, and investors are eager to see a consistent upward trend.
Bull confirmed if
An EPS of $0.73 or higher would confirm the bull case and suggest a recovery in profitability.
Bear confirmed if
An EPS below $0.59 would reinforce concerns about the company's financial health.
What the market is pricing for the move.
Implied Move
±3.96%
Historical Avg
±2.0%
The options market is pricing in a potential move of nearly 4%, indicating uncertainty about the upcoming earnings report.
Options are pricing ±4.0% while SLNO has averaged ±2.0% over the last 8 prints — setup is pricing rich.
30d HV
81.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Soleno beats expectations, history suggests the stock could rise by around 2.04%, confirming a positive trend.
In line / cautious
If results are in line with expectations, the stock may see minimal movement as investors await further guidance.
Miss
A miss could lead to a decline, with historical data indicating an average drop of around 0.20% following earnings misses.
The lines on the call that would change the story.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—